SGS has launched Simulo, an in-silico modeling and simulation platform designed to facilitate complex clinical trial simulation to predict the expected results of prospective trials, as well as optimize study design to help facilitate a successful efficacy and safety outcome.
 
Simulo offers a software solution which implements pharmacokinetic (PK), pharmacodynamic (PD) and disease progression models, in an accessible interface. This simulation tool was designed to explore the time course of drug exposure, biomarker response and outcome – therapeutic and adverse – observed in clinical studies, in both the individual subject and at population level.
 
Two versions of Simulo software are available, a “Standard” version, which is free of charge, where operators can take part in a one or two-day training program, and an “Expert” version, which comes with a scientific support package to collaborate with SGS Exprimo specialists when performing advanced clinical trial simulations.
 
“Simulation of clinical trial outcomes has always been cumbersome to conduct in a scientifically adequate way, requiring the writing of extensive computer programming code to account for the various levels of uncertainty. These include adaptive dosing schedules, heterogeneous study populations and patient dropout due to adverse events,” said Daniel Röshammar, SGS Exprimo Scientific Director. “By sharing this software with our clients, we can help them to more easily reach the full potential of simulation techniques, resulting in more innovative and successful clinical trial designs, and may offer a strong research advantage.”